[HTML][HTML] Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
N Mao, Z Zhang, YS Lee, D Choi, AA Rivera… - Nature …, 2021 - nature.com
Previous studies have suggested that PTEN loss is associated with p110β signaling
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers.
N Mao, Z Zhang, YS Lee, D Choi, AA Rivera… - Nature …, 2021 - europepmc.org
Previous studies have suggested that PTEN loss is associated with p110β signaling
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
N Mao, Z Zhang, YS Lee, D Choi… - Nature …, 2021 - econpapers.repec.org
Previous studies have suggested that PTEN loss is associated with p110β signaling
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers.
N Mao, Z Zhang, YS Lee, D Choi… - Nature …, 2021 - search.ebscohost.com
Previous studies have suggested that PTEN loss is associated with p110β signaling
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
N Mao, Z Zhang, YS Lee, D Choi, AA Rivera… - Nature …, 2021 - ideas.repec.org
Previous studies have suggested that PTEN loss is associated with p110β signaling
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
[HTML][HTML] Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
N Mao, Z Zhang, YS Lee, D Choi, AA Rivera… - Nature …, 2021 - ncbi.nlm.nih.gov
Previous studies have suggested that PTEN loss is associated with p110β signaling
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
N Mao, Z Zhang, YS Lee, D Choi… - Nature …, 2021 - ui.adsabs.harvard.edu
Previous studies have suggested that PTEN loss is associated with p110β signaling
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
N Mao, Z Zhang, YS Lee, D Choi… - Nature …, 2021 - pubmed.ncbi.nlm.nih.gov
Previous studies have suggested that PTEN loss is associated with p110β signaling
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …
dependency, leading to the clinical development of p110β-selective inhibitors. Here we use …